Indications for use of Mexidol (Emoxypine) are:

The consequences of acute disorders of cerebral circulation, including after transient ischemic attacks, in the phase of subcompensation as preventive courses;

Slight traumatic brain injury, the consequences of traumatic brain injury;

Encephalopathy of various origins (discirculatory, dysmetabolic, post-traumatic, mixed);

Autonomic dystonia syndrome;

Mild cognitive disorders of atherosclerotic genesis;

Anxiety disorders in neurotic and neurosis-like states;

Ischemic heart disease as part of complex therapy;

Relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders, post-withdrawal disorders;

Conditions after acute intoxication with antipsychotic drugs;

Asthenic conditions, as well as for the prevention of the development of somatic diseases under the influence of extreme factors and loads;

Exposure to extreme (stress) factors.

 Description:

Tablets are round, biconvex, film-coated, from white to white with a creamy shade.

  Pharmacological properties:

Pharmacodynamics:

Mexidol® is an inhibitor of free radical processes, a membrane protector with antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects. The drug increases the body's resistance to the effects of various damaging factors (shock, hypoxia and ischemia, cerebrovascular accidents, alcohol and antipsychotic drugs (neuroleptics) intoxication).

The mechanism of action of Mexidol® is due to its antioxidant, antihypoxant and membrane-protective action. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity. Mexidol® modulates the activity of membrane-bound enzymes (calcium independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, contributes to the preservation of the structural and functional organization of biomembranes and transport of neuromembranes. Mexidol® increases the content of dopamine in the brain. It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, and stabilization of cell membranes.

The drug improves metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, reduces platelet aggregation. It stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces the content of total cholesterol and low density lipoproteins.

The antistress effect is manifested in the normalization of post-stress behavior, somatovegetative disorders, restoration of sleep-wakefulness cycles, impaired learning and memory processes, reduction of dystrophic and morphological changes in various structures of the brain.

Mexidol® has a pronounced antitoxic effect in withdrawal symptoms. It eliminates the neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral disturbances, autonomic functions, and is also able to relieve cognitive impairment caused by prolonged intake of ethanol and its withdrawal. Under the influence of Mexidol®, the effect of tranquilizing, neuroleptic, antidepressant, hypnotic and anticonvulsants is enhanced, which allows them to reduce their doses and reduce side effects. Mexidol® improves the functional state of the ischemic myocardium. In conditions of coronary insufficiency, it increases collateral blood supply to the ischemic myocardium, contributes to the preservation of the integrity of cardiomyocytes and the maintenance of their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction.

  Pharmacokinetics:

It is rapidly absorbed when taken orally. The maximum concentration at doses of 400 - 500 mg is 3.5 - 4.0 μg / ml. It is quickly distributed in organs and tissues. The average retention time of the drug in the body when ingested is 4.9 - 5.2 hours. It is metabolized in the liver by glucuron conjugation. 5 metabolites have been identified: 3-hydroxypyridine phosphate - formed in the liver and, with the participation of alkaline phosphatase, decomposes into phosphoric acid and 3-hydroxypyridine; 2nd metabolite - pharmacologically active, is formed in large quantities and is found in the urine 1 - 2 days after administration; 3rd - excreted in large quantities in the urine; 4th and 5th - glucuron conjugates. T1 / 2 when taken orally - 2.0 - 2.6 hours. It is quickly excreted in the urine, mainly in the form of metabolites and in small quantities - unchanged. It is most intensively excreted during the first 4 hours after taking the drug. The indicators of excretion in the urine of unchanged drug and metabolites have individual variability.

 Release form:

Film-coated tablets, 125 mg. On 10 tablets in a blister strip of a film of polyvinyl chloride and aluminum foil. 1, 2, 3, 4, 5 blister packs with instructions for use in a cardboard box.